Lipoprotein(a) is Associated with Increased Low-Density Plaque Volume

Rebecca Fisher; Nick Nurmohamed; Edward A. Fisher; Melissa Aquino; James P. Earls; James K. Min; Chen Gurevitz; Waqas A. Malick; M. Robert Peters; Sascha N. Goonewardena; Robert S. Rosenson

doi:10.1101/2024.07.18.24310539

Abstract

BACKGROUND Lipoprotein(a) [Lp(a)] is an inherited risk factor for cardiovascular disease that is accompanied by a more severe coronary artery disease (CAD) phenotype and a higher risk for events. The objective of this study is to clarify the association between Lp(a) and coronary plaque characteristics in asymptomatic patients.

METHODS 373 consecutive asymptomatic patients were evaluated for primary prevention of CAD. Artificial intelligence quantitative coronary CTA (AI-QCT) was used to investigate the relationship between Lp(a) and coronary plaque characteristics. Multivariable linear regression adjusted for CAD risk factors (age, sex, race, diabetes, smoking), statin use, and body mass index were used to analyze associations between the Lp(a) (by quintile), high sensitivity C-reactive protein (hsCRP), coronary artery calcium (CAC) score, and AI-QCT findings. AI-QCT findings were defined as low-density non-calcified plaque volume (LD-NCPV).

RESULTS The mean age was 56.2±8.9 years, 71.6% were male, and 54.2% were taking statin therapy. Median LDL-C was 103(72,136)mg/dL, median Lp(a) was 31(11, 89)nmol/L, median Lp(a) corrected LDL-C was 101(64, 131)mg/dL. Median hsCRP levels were 0.8(0.4, 1.8)mg/L. Median CAC levels were 6.0(0.0,110.0). There was no association between Lp(a) concentrations and CAC(P=0.281). After adjustment for CAD risk factors, every quintile of Lp(a) increase was associated with a 0.4% increase in LD-NCPV(P=0.039). The inclusion of hsCRP to the models had no significant effect on LD-NCPV.

CONCLUSIONS Higher Lp(a) concentrations in asymptomatic patients are significantly associated with increased low-density non-calcified plaque volume.

Clinical Perspective Lp(a) is a risk marker for early-onset coronary heart disease events. Early detection of vulnerable patients is critical to mitigating this risk that may be inadequately captured by the coronary artery calcium score. Low-density non-calcified plaque quantification by coronary computerized tomography is an approach that may be more suitable to assess risk in patients with high Lp(a) levels.

Competing Interest Statement

NSN reports grants from Dutch Heart Foundation (Dekker 03-007-2023-0068) and European Atherosclerosis Society (2023) and is co-founder of Lipid Tools. MA, JKM and JPE are employees of Cleerly Inc. SG receives funding from CSR&D Merit (1I01CX002560). RSR reports research funding to his institution from Amgen, Arrowhead, Eli Lilly, Merck, NIH, Novartis, Novo Nordisk, and 89Bio, consulting fees from Amgen, Avilar, CRISPER Therapeutics, Eli Lilly, Lipigon, New Amsterdam, Novartis, Precision Biosciences, Regeneron, UltraGenyx, Verve Therapeutics, non-promotional honoraria from Meda Pharma, royalties from Wolters Kluwer (UpToDate), and stock holding in MediMergent, LLC. He reports patent applications on: Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device. EFS ID: 32278349. Application No. (PCT/US2019/026364) (provisional); Compositions and methods relating to the identification and treatment of immunothrombotic conditions. New International Application No. (PCT/US2021/63104926); and quantification of Lp(a) vs. non-Lp(a) apoB concentration: development of a novel validated equation. (PCT/US2021/63248837). The other authors report no disclosures.

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board (IRB) of the Program for the Protection of Human Subjects at Icahn School of Medicine at Mount Sinai determined that the study (IRB ID: STUDY-24-00151) is not research involving human subjects as defined by the United States Department of Health and Human Services and Food and Drug Administration. The IRB of the Icahn School of Medicine at Mount Sinai waived ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes